Straumann Holding AG EBITDA 2012-2021 | SAUHY
Straumann Holding AG annual and quarterly EBITDA history from 2012 to 2021. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Straumann Holding AG EBITDA for the quarter ending December 31, 2021 was $M, a NAN% increase year-over-year.
- Straumann Holding AG EBITDA for the twelve months ending December 31, 2021 was $0M, a NAN% increase year-over-year.
- Straumann Holding AG 2021 annual EBITDA was $0.707B, a 158.76% increase from 2020.
- Straumann Holding AG 2020 annual EBITDA was $0.273B, a 43.56% decline from 2019.
- Straumann Holding AG 2019 annual EBITDA was $0.484B, a 19.79% increase from 2018.
Straumann Holding AG Annual EBITDA
(Millions of US $) |
| 2021 |
$707 |
| 2020 |
$273 |
| 2019 |
$484 |
| 2018 |
$404 |
| 2017 |
$329 |
| 2016 |
$257 |
| 2015 |
$214 |
| 2014 |
$193 |
| 2013 |
$156 |
| 2012 |
$100 |
| 2011 |
$175 |
Straumann Holding AG Quarterly EBITDA
(Millions of US $) |
| 2021-12-31 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2018-12-31 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2014-12-31 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$22.515B |
$2.845B |
|
The Straumann Group is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately on thousand seven hundred ninety people worldwide and its products and services are available in more than sixty countries through its broad network of distribution subsidiaries and partners.
|
